Laboratory Records
PEPTIDES BIO / MATERIAL RECORD
Tirzepatide 10mg
Research-use peptide material record: pack format, specifications and COA/SDS request for qualified laboratory review.
RESEARCH USE ONLYRUO
Tirzepatide 10mg
Important NoticeThis product is for use only in vitro research. It is strictly prohibited for human injection, clinical treatment, food addition or any animal experiments. Please read our terms and conditions carefully before placing an order.
Volume pricing
Configured totals update at each quantity threshold.
Configured total$38.76
Request COA / MSDS
Research record
Pending manual confirmationResearch overview
Tirzepatide is a synthetic linear polypeptide comprising 39 amino acids. It features a C20 fatty acid diacid side‑chain modification that enhances serum albumin binding, thereby prolonging its half‑life in vivo. Tirzepatide acts as a dual agonist at the glucose‑dependent insulinotropic polypeptide (GIP) and glucagon‑like peptide‑1 (GLP‑1) receptors. As a single molecule, it selectively binds to and activates both GIPR and GLP‑1R. Receptor pharmacology studies indicate that while Tirzepatide engages hGIPR in a manner similar to native GIP, it exhibits a biased signaling profile at GLP‑1R, favoring cAMP production over β‑arrestin recruitment. Through this dual agonism, Tirzepatide enhances both first‑ and second‑phase glucose‑dependent insulin secretion and concurrently reduces glucagon levels.
Research reference
Product FAQ
What is Tirzepatide?
A dual GIP and GLP-1 receptor agonist peptide that delivers outstanding glucose-lowering and weight-loss effects—a next-generation therapy for metabolic disorders.
What is the mechanism of action of Tirzepatide?
Tirzepatide is a dual agonist that activates both GIP and GLP-1 receptors. GIP enhances insulin sensitivity in adipose tissue and promotes lipid buffering, while GLP-1 suppresses appetite and delays gastric emptying. The two work synergistically to achieve potent glucose-lowering and weight-loss effects.
What about Tirzepatide and fatty liver disease?
Clinical data show that tirzepatide significantly reduces liver fat content (by MRI‑PDFF) and serum ALT/AST levels. Phase 3 trials for MASH are ongoing, with promising preliminary results.
What advantages does Tirzepatide have over other GLP‑1 drugs?
Its dual‑target (GIP+GLP‑1) mechanism is its core advantage. Compared with single‑target GLP‑1 drugs, tirzepatide shows superior weight loss, glycemic control (HbA1c reduction), and lipid improvement. Its once‑weekly long‑acting design also enhances convenience.
What are the main research areas for Tirzepatide?
· Obesity and weight management
· Type 2 diabetes and glycemic control
· Obstructive sleep apnea (OSA)
· Non‑alcoholic fatty liver disease (NAFLD) / Metabolic dysfunction‑associated steatohepatitis (MASH)
· Cardiovascular health (including heart failure with preserved ejection fraction)
· Chronic kidney disease
Data sheet
Manual confirmation- Material Type
- Single material
- Purity Identity
- ≥99% purity
- Molecular Weight
- 4813.45 g/mol
- Pack Size
- 10mg
- Molecular Formula
- C225H348N48O68
- CAS Number
- 2023788-19-2
- Amino Acid Sequence
- 4813.45 g/mol
- PubChem CID
- 168009818
- Storage conditions overview
- Storage typelong-termTemperature-80°CDuration2-3 yearsNotesSealed, dark, minimal openingStorage typeStandardTemperature-20°CDuration1-2 yearsNotesSealed, dark, moisture-proofStorage typeShort-termTemperature4°CDuration1-2 weeksNotesTemporary storage, use promptlyStorage typeWorking SolutionTemperature4°CDuration1-7 daysNotesReconstituted, short-term, avoid freeze-thaw
Related research guides